Interstitial Cystitis Global Market Report 2024

The global interstitial cystitis market has grown strongly in recent years. It will grow from $1.69 billion in 2023 to $1.83 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to advancements in diagnosis, awareness and education, pharmaceutical developments, supportive therapies.

The global interstitial cystitis market is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to biomarker research, innovative medications, patient-centered care, global expansion. Major trends in the forecast period include dietary guidance, interdisciplinary care, research collaboration, alternative therapies.

The increasing prevalence of urinary tract infections (UTIs) is anticipated to drive the expansion of the interstitial cystitis market. UTIs are bacterial infections that can affect any part of the urinary system and are typically caused by bacteria entering the urethra. UTIs can directly or indirectly trigger bacterial cystitis and when left untreated, can result in persistent bladder inflammation, which is the underlying cause of interstitial cystitis. Treating UTIs linked to interstitial cystitis not only alleviates pain but also enhances the quality of life for patients grappling with this condition. For example, in 2021, data from the Centers for Disease Control and Prevention, a US-based national public health agency, reported approximately 24,710 catheter-associated urinary tract infections in the US. Additionally, according to an article published by The British Society for Antimicrobial Chemotherapy, a UK-based multi-professional organization, nearly half of all women in the United Kingdom are estimated to experience at least one urinary tract infection (UTI) at some point in their lives. Hence, the surging prevalence of UTIs propels the interstitial cystitis market.

The burgeoning governmental initiatives are poised to propel the growth of the interstitial cystitis market. Government initiatives represent strategic plans or actions taken by governments to address specific issues or problems, often funded through various sources such as taxes, grants, and donations. In the context of interstitial cystitis (IC), government initiatives play a crucial role in supporting fundamental research to enhance the understanding of IC's causes and mechanisms. They also provide funding for clinical trials aimed at testing novel treatments and therapies. For instance, in June 2023, the Food and Drug Administration, a US-based federal agency responsible for public health protection, introduced an initiative focused on a drug development program for the treatment and the creation of products designed to address interstitial cystitis or bladder pain syndrome. Therefore, the increasing government initiatives drive the interstitial cystitis market.

The growth of the interstitial cystitis market is being impeded by the high costs associated with treatment during the forecast period. Elevated treatment costs can create financial barriers that limit patients' access to essential care. Some individuals may opt to forego seeking treatment altogether, while others may delay treatment until their condition worsens, ultimately having a detrimental effect on the overall market. For instance, as reported by the American Hospital Association, a professional organization, hospital prices increased by 2.1% over the year leading up to February 2022. Consequently, the substantial cost of treatment hinders the growth of the interstitial cystitis market.

Prominent companies operating in the interstitial cystitis treatment market are dedicated to the development of cutting-edge products, including intravesical solutions, to address interstitial cystitis and drive market revenues. Innovative treatments, such as intravesical solutions for interstitial cystitis, enhance the care and outcomes for individuals grappling with this chronic and often intricate bladder condition. As an illustration, in April 2021, Kyorin Pharmaceutical Co Ltd., a Japan-based developer and manufacturer of prescription medicines and quasi-drugs, introduced Interstitial cystitis Zymso Intravesical Solution 50%, a dimethyl sulfoxide (DMSO) bladder instillation. This solution, uniquely formulated with DMSO, is administered into the bladder through a catheter to alleviate pain and discomfort associated with IC. The recommended dosage for adults involves six injections of 50 mL of a 50% (w / w) dimethyl sulfoxide solution (equivalent to 27g of dimethyl sulfoxide) at two-week intervals.

In July 2021, Pharmavite, a US-based dietary supplement company, completed the acquisition of Uqora Inc. for an undisclosed sum. This strategic acquisition is expected to empower Pharmavite to enhance and diversify its product offerings in the women's urinary health market. Uqora Inc., a US-based developer of supplements and solutions aimed at reducing the risk of urinary infections and addressing bladder issues such as interstitial cystitis and chronic UTIs, complements Pharmavite's commitment to women's urinary health.

Major players in the interstitial cystitis market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim international GmbH, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Perrigo Company PLC, Aurobindo Pharma Ltd., Purdue Pharma LP, Apotex Inc., Endo International PLC, Amneal Pharmaceuticals Inc., Alvogen Inc., Kyorin Pharmaceutical Co. Ltd., Seikagaku Corp, Genentech Inc., Strides Pharma Science Limited, AlgoTherapeutix SAS.

North America was the largest region in the interstitial cystitis market in 2023. The regions covered in interstitial cystitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interstitial cystitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatments for interstitial cystitis include medications, bladder instillation, botulinum toxin A, nerve stimulation, and surgical interventions. Interstitial cystitis medications encompass a range of drugs and therapeutic approaches employed to manage the symptoms of this chronic bladder inflammation condition. These treatments are designed for both pediatric and adult patients and encompass various drug types, including over-the-counter (OTC) and prescription medications. The end users of these treatments include hospitals, clinics, and home care settings.

This report provides interstitial cystitis market statistics, including interstitial cystitis industry global market size, regional shares, competitors with a interstitial cystitis market share, detailed interstitial cystitis market segments, market trends and opportunities and any further data you may need to thrive in the interstitial cystitis industry. This interstitial cystitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The interstitial cystitis market include revenues earned through entities by providing services such as physical therapy, oral medications, nerve stimulation and bladder distention. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.